Main clinical and biological characteristics of 146 patients diagnosed with CLL at age ≤50 y according to TLR/MYD88 mutations
| Characteristic or outcome . | Unmutated (n = 127) . | Mutated (n = 19) . | P . | ||
|---|---|---|---|---|---|
| No. . | % . | No. . | % . | ||
| Male gender | 85 | 67 | 13 | 68 | NS |
| Age, years | NS | ||||
| Median | 44 | 43 | |||
| Range | 24-50 | 32-49 | |||
| Binet stage | .046 | ||||
| A | 89/126 | 71 | 13/19 | 68 | |
| B | 33/126 | 26 | 3/19 | 16 | |
| C | 4/126 | 3 | 3/19 | 16 | |
| Rai stage | |||||
| 0 | 44/126 | 35 | 3/19 | 16 | |
| I-II | 77/126 | 61 | 13/19 | 68 | .045 |
| III-IV | 5/126 | 4 | 3/19 | 16 | |
| Monoclonal component | 7/127 | 6 | 4/19 | 21 | .038 |
| β2-microglobulin, UNV | 40/103 | 39 | 1/15 | 7 | .013 |
| LDH, UNV | 15/113 | 13 | 1/17 | 6 | NS |
| LDT <1 y | 18/79 | 23 | 1/13 | 8 | NS |
| Mutated IGHV | 43/99 | 44 | 15/17 | 88 | <.001 |
| <30% CD38 | 64/106 | 60 | 17/18 | 94 | .006 |
| <20% ZAP-70 | 53/100 | 53 | 18/18 | 100 | <.001 |
| Genetics | |||||
| del(13q)(q14.3) | 34/84 | 40 | 8/14 | 57 | NS |
| Trisomy 12 | 11/85 | 13 | 1/14 | 7 | NS |
| del(11q)(q22.3) | 12/83 | 14 | 1/14 | 7 | NS |
| del(17p)(p13.1) | 3/83 | 4 | 0/14 | 0 | NS |
| Mutated NOTCH1 | 9/112 | 8 | 0/18 | 0 | NS |
| Mutated SF3B1 | 10/86 | 12 | 1/14 | 7 | NS |
| Mutated TP53 | 2/73 | 3 | 0/13 | 0 | NS |
| Treated patients | 92/127 | 73 | 10/19 | 53 | NS |
| 10-y TTT for Binet A and B patients (%) | 74 | 37 | .07 | ||
| 95% CI | 65-83 | 11-64 | |||
| 10-y OS for all patients (%) | 70 | 100 | .02 | ||
| 95% CI | 65-75 | ||||
| Characteristic or outcome . | Unmutated (n = 127) . | Mutated (n = 19) . | P . | ||
|---|---|---|---|---|---|
| No. . | % . | No. . | % . | ||
| Male gender | 85 | 67 | 13 | 68 | NS |
| Age, years | NS | ||||
| Median | 44 | 43 | |||
| Range | 24-50 | 32-49 | |||
| Binet stage | .046 | ||||
| A | 89/126 | 71 | 13/19 | 68 | |
| B | 33/126 | 26 | 3/19 | 16 | |
| C | 4/126 | 3 | 3/19 | 16 | |
| Rai stage | |||||
| 0 | 44/126 | 35 | 3/19 | 16 | |
| I-II | 77/126 | 61 | 13/19 | 68 | .045 |
| III-IV | 5/126 | 4 | 3/19 | 16 | |
| Monoclonal component | 7/127 | 6 | 4/19 | 21 | .038 |
| β2-microglobulin, UNV | 40/103 | 39 | 1/15 | 7 | .013 |
| LDH, UNV | 15/113 | 13 | 1/17 | 6 | NS |
| LDT <1 y | 18/79 | 23 | 1/13 | 8 | NS |
| Mutated IGHV | 43/99 | 44 | 15/17 | 88 | <.001 |
| <30% CD38 | 64/106 | 60 | 17/18 | 94 | .006 |
| <20% ZAP-70 | 53/100 | 53 | 18/18 | 100 | <.001 |
| Genetics | |||||
| del(13q)(q14.3) | 34/84 | 40 | 8/14 | 57 | NS |
| Trisomy 12 | 11/85 | 13 | 1/14 | 7 | NS |
| del(11q)(q22.3) | 12/83 | 14 | 1/14 | 7 | NS |
| del(17p)(p13.1) | 3/83 | 4 | 0/14 | 0 | NS |
| Mutated NOTCH1 | 9/112 | 8 | 0/18 | 0 | NS |
| Mutated SF3B1 | 10/86 | 12 | 1/14 | 7 | NS |
| Mutated TP53 | 2/73 | 3 | 0/13 | 0 | NS |
| Treated patients | 92/127 | 73 | 10/19 | 53 | NS |
| 10-y TTT for Binet A and B patients (%) | 74 | 37 | .07 | ||
| 95% CI | 65-83 | 11-64 | |||
| 10-y OS for all patients (%) | 70 | 100 | .02 | ||
| 95% CI | 65-75 | ||||